Results 71 to 80 of about 42,994 (252)

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Emerging insights into amino acid metabolism in the heart: implications for cardiovascular diseases and therapeutic targeting

open access: yesBritish Journal of Pharmacology, EarlyView.
As a metabolically versatile organ, the heart is capable of generating energy from a wide range of substrates. Although fatty acid and glucose metabolism in the heart have been extensively studied, the contribution of amino acid metabolism to cardiac physiology and disease is gaining increasing attention.
Tayyiba Azam   +6 more
wiley   +1 more source

Characteristics and risk factors associated with developing prediabetes in Saudi Arabia

open access: yesAnnals of Medicine
Objective Prediabetes is prevalent in Saudi Arabia and globally. It is associated with adverse health outcomes and complications. Consequently, this study aimed to determine the risk factors associated with developing prediabetes in Saudi Arabia.Methods ...
Ayla M. Tourkmani   +7 more
doaj   +1 more source

Defining Age to Screen and Real‐World Effectiveness for Early‐Onset Colorectal Cancer

open access: yesCancer Science, EarlyView.
Implementation of a RAP‐based risk‐adapted screening strategy enables personalized screening initiation, with benefits comparable to those observed in the current 50–54‐year age group.
Le Wang   +8 more
wiley   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Global epidemiology of prediabetes - present and future perspectives

open access: yesClinical Diabetes and Endocrinology, 2019
Prediabetes is defined as an intermediate state of hyperglycaemia with glucose levels above the normal state but below the diagnostic levels of diabetes.
Ulrike Hostalek
doaj   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton   +4 more
wiley   +1 more source

Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Binge eating disorder frequently co‐occurs with type 2 diabetes, creating a dual burden that may complicate both psychological well‐being and glycaemic management. Evidence on the effectiveness of health interventions in this population is limited.
Pernille Fiil Nybo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy